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Abstract.EphrinA1 is a tyrosine kinase receptor localized in the cellular membrane of
healthy cardiomyocytes, the expression of which is lost upon myocardial infarction
(MI). Intra-cardiac injection of the recombinant form of ephrinA1 (ephrinA1-Fc) at the
time of ligation in mice has shown beneficial effects by reducing infarct size and
myocardial necrosis post-MI. To date, immunohistochemistry and Western blotting
comprise the only experimental approaches utilized to localize and quantify relative
changes of ephrinA1 in sections and homogenates of whole left ventricle, respec-
tively. Herein, we usedmatrix-assisted laser desorption ionizationmass spectrometry
imaging (MALDI-MSI) coupled with a time-of-flight mass spectrometer (MALDI/TOF
MS) to identify intact as well as tryptic fragments of ephrinA1 in healthy controls and
acutely infarctedmurine hearts. The purpose of the present studywas 3-fold: (1) to spatially resolve themolecular
distribution of endogenous ephrinA1, (2) to determine the anatomical expression profile of endogenous ephrinA1
after acute MI, and (3) to identify molecular targets of ephrinA1-Fc action post-MI. The tryptic fragments detected
were identified as the ephrinA1-isoform with 38% and 34% sequence coverage and Mascot scores of 25 for the
control and MI hearts, respectively. By using MALDI-MSI, we have been able to simultaneously measure the
distribution and spatial localization of ephrinA1, as well as additional cardiac proteins, thus offering valuable
information for the elucidation of molecular partners, mediators, and targets of ephrinA1 action in cardiacmuscle.
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Introduction
Heart disease represents a staggering burden in the US interms of survival rates and healthcare costs [1, 2]. High
rates of mortality associated with myocardial infarction (MI),
and especially with recurrent MIs, indicate the need for novel
diagnostic and therapeutic methods. EphrinA1 is a tyrosine
kinase receptor expressed in the cellular membrane of
cardiomyocytes. After myocardial injury, cardiomyocytes be-
come necrotic or damaged, which leads to a substantial
reduction in ephrinA1 protein levels. Immunohistochemical
studies have shown that cell surface expression of the endog-
enous ephrinA1 ligand decreases in injured cardiomyocytes
during an MI [1, 2]. However, a recent study showed that
intra-cardiac injection of recombinant ephrinA1-Fc post-MI
reduced infarct size, cardiomyocyte necrosis, chamber dilation,
and left ventricular free wall thinning in mice [2]. The benefi-
cial effects on cardiac function observed with ephrinA1-Fc
treatment indicate that this molecule is a promising, novel
therapeutic for MI treatment. However, the precise molecular
mechanism(s) by which exogenously administered ephrinA1-
Fc prevents cardiomyocyte death post-MI remain unknown.
With intra-myocardial levels of ephrinA1 following an MI
being positively correlated with favorable outcomes, insights
into ephrinA1 intracellular signaling pathways suggest that
blocking apoptosis and inflammation, as well as promoting
autophagy, could represent potential mechanisms of action
[2, 3]. A more in-depth understanding of the molecular
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distribution of ephrinA1 and its mediators in cardiac tissue is
vital for the identification of targets that could minimize car-
diomyocyte death and prevent heart failure following MI.
Previous studies have provided qualitative information on the
molecular distribution of ephrinA1 via immunohistochemistry,
as well as relative quantitative data by Western blotting of
tissue homogenates [1]. However, the large number of chro-
mogens or fluorochromes that can cause interference, as well as
their different subcellular localization, significantly limits the
number of proteins that can be identified simultaneously using
immunohistochemical techniques; and Western blotting per se
fails at deciphering a protein’s true anatomical distribution.
Matrix-assisted laser desorption ionization mass spectrometry
imaging (MALDI-MSI) allows for the acquisition of spatial
distribution maps of molecular species in situ, allowing the
examination of the molecular architecture in complex biologi-
cal matrices, and has thus been proposed as a molecular histol-
ogy tool to compliment in the study of pathophysiology [4, 5].
MALDI-MSI has demonstrated to be an effective tool for
probing metabolites, lipids, and proteins in a variety of samples
and tissues [4, 6–8]. When coupled with a time-of-flight mass
spectrometer, MALDI-MSI covers a large mass range and has
the ability to execute both intact and enzymatically digested
protein analysis [9]. MALDI-MSI enables us to simultaneously
detect the distribution and localization of ephrinA1, and thus
elucidate its molecular partners, mediators, and targets of action
[10–14]. Therefore, the primary goals of this study were: (1) to
optimize an effective protocol to spatially resolve the molecular
distribution of endogenous ephrinA1 using MALDI-MSI, (2)
to determine and compare the anatomical expression profile of
ephrinA1 in healthy control hearts versus post-acute MI, and




Water, acetonitrile (ACN), and trifluoroacetic acid (TFA) were
Optima Grade purchased from Thermo Fisher Scientific
(Hampton, NH, USA). Calibration mixture including angioten-
sin II, bovine insulin, polyethylene glycol 600, and MALDI
matrices 2′,5′-dihydroxyacetophenone (DHA), 3,5-dimethoxy
4-hydroxycinnamic acid (sinapinic acid, SA), and α-cyano-4-
hydroxycinnamic acid (CHCA) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Indium tin oxide (ITO)-coated
conductive glass microscope slides were purchased from
Bruker Daltonics (Billerica, MA, USA). Sequencing grade
trypsin was purchased from Promega (Madison, WI, USA).
Accu-Edge low profile blades (4689) were purchased from
VWR (Radnor, PA, USA).
Analytical Standard Preparation
Ephrin-A1 (His tag) was purchased from NovoPro Lab
(501312) and diluted to a concentration of 0.1 μg/μL in
phosphate-buffered saline (PBS). For all sample slides and
method development, 1 μL of the former solution was spotted
on an ITO-conductive slide for MALDI analysis 1:1 with 10
mg/mL SA dissolved in 60:40 ACN:water, containing 0.07%
TFA. The intact protein was analyzed using linear MALDI/
TOF MS in positive ionization mode.
Animal Use
Experimental research protocols were approved by the East
Carolina University Institutional Animal Care and Use Com-
mittee (IACUC) following the guidelines of the National Insti-
tutes of Health for the Care and Use of Laboratory Animals.
Male (8–12 wk-old) B6129SF2/J mice (stock #101045) were
purchased from The Jackson Laboratory. All mice were housed
in ventilated cages, exposed to 12 h/12 h light/dark cycle
conditions, and received food and water ad libitum. The De-
partment of Comparative Medicine at The Brody School of
Medicine, East Carolina University, maintained animal care.
Mice were divided in two groups: uninjured control (CTL, n =
10) and acute myocardial infarction (MI, n = 6), induced by a 4-
d permanent occlusion of the left anterior descending coronary
artery (LAD).
Surgical Procedure and Tissue Collection
Mice were anesthetized with an intraperitoneal injection of
Avertin (20 mg/Kg body weight, BW) and mechanically ven-
tilated with 95% O2/5% CO2. A thoracotomy was performed
and myocardial infarction was induced by occluding the LAD
using an 8-0 suture. Ischemia was confirmed by visible
blanching of the tissue distal to occlusion. The rib cage, muscle,
and skin were closed sequentially and the animals were
allowed to recover over a heating pad. Four days post-MI,
animals were anesthetized with euthasol (100 mg/Kg BW)
and sacrificed for tissue harvest. Whole hearts were thoroughly
perfused with ice-cold PBS (10–15 mL over 2–3 min) to
remove residual blood, wrapped loosely in foil, and snap-
frozen in liquid nitrogen. Samples were then stored overnight
at –80 °C.
Tissue Preparation and Cryosectioning
Freshly frozen hearts were mounted to a cryostat chuck with
HPLC grade water in a dry ice container to freeze and fuse the
tissue in place for sectioning. Orientation of the tissue was
traverse distal to ligation of LAD in infarcted hearts. Tissue
was sectioned at ~10 μm thickness, thaw-mounted onto ITO-
conductivemicroscope slides, and maintained at –20 °C. Slides
were then sequentially rinsed in 70%, 90%, and 95% ethanol
diluted in HPLC grade water for ~30 s each, and then placed
into a vacuum desiccator containing Drierite for 20–30 min
[13, 14].
Selection of Optimal Matrix
Three matrices were tested for optimal detection of ephrinA1
standard: DHA, CHCA, and SA. All matrices were tested at 10
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mg/mL in 70:30 acetonitrile:water with 0.3% TFA, 60:40
acetonitrile:water with 0.1% TFA, and 70:30 acetonitrile:water
with 0.1% TFA. EphrinA1 standard was spotted with matrix
1:1 on a target plate and the intact protein signal was used to
optimize the MALDI instrument parameters in positive ioniza-
t ion mode . The 10 mg/mL SA matr ix in 70:30
acetonitrile:water with 0.3% TFA was found to provide the
highest degree of detection and was selected for the rest of the
study.
Intact EphrinA1 MALDI Matrix Applications
For method development and optimization, three methods for
matrix deposition were tested utilizing standards and control
tissue for intact protein analysis: (1) direct delivery, (2) thin
layer chromatography (TLC) sprayer (Sigma-Aldrich,
Z529710, 10 mL), and (3) TM sprayer (HTX Imaging). (1)
For the first experiment, 0.5 μL of the SA matrix was applied
using a micropipette in multiple regions across the control
tissue for intact ephrinA1 signal optimization and mixed 1:1
with the analytical standard next to the tissue for mass calibra-
tion and verification. (2) A TLC sprayer was manually used to
apply SA matrix and the standard was applied near the tissue
after matrix deposition. N2 was used at a low flow rate (< 5 psi)
and psi was optimized based on the spray distribution. Two
spray passes were performed before allowing the slides to
completely dry. This process was repeated to add and build
layers of matrix using a total of 20 mL of matrix. (3) A TM
sprayer was used to apply SA matrix under the following
conditions: 0.1 mL/min solvent flow rate, 10 psi N2 gas pres-
sure, 30 °C nozzle temperature, 750 mm/min velocity, spacing
of 2 mm, and four passes.
Trypsin Sample Digestion
For the preparation of the trypsin solution, 20 μL of
sequencing-grade trypsin (1 μg/μL) was added to 333 μL
sodium bicarbonate 100 mM containing 0.01% ammonium
hydroxide, 40 μL acetonitrile, and 67 μL acetic acid, for a total
volume of 460 μL. The solution was prepared and incubated at
37 °C for activation prior to application on the tissue using the
TM sprayer. After trypsin application, samples were incubated
at 37 °C for 1, 3, and 4 h. SA matrix was applied using the TM
sprayer to stop the trypsin reaction, and samples were prepared
for imaging.
Mass Spectrometry Imaging
Imaging experiments were performed using a Bruker Autoflex
Speed MALDI/TOF-TOF mass spectrometer. Before matrix
deposition, tissues were scanned using an Epson flatbed scan-
ner and collected at 300 dpi for acquisition of a digital baseline
image. The mass spectrometer method was set to collect 5000
spectra/spot and images. Intact protein images were collected
using linear mode, and trypsin peptide images were collected
using reflectron mode. Calibration was conducted using a
mixture of angiotensin II, bovine insulin, PEG 600, and
ephrinA1-His standard. All control and acute MI samples were
imaged at 100 μm spatial resolution. Data was collected in
positive ionization mode and a Nd:YAG laser repetition rate of
2000 Hz was used (50 μm laser size) during image collection.
Data Analysis
Imaging data was processed using FlexImaging (Bruker) and
the mass spectra were analyzed in FlexAnalysis (Bruker).
Images were normalized using a unit vector algorithm. The
murine ephrinA1 protein sequence (NCBI accession number
NP_034237) was used with the MS-Digest program at http://
prospector.ucsf.edu/ to predict theoretical peptide fragments
from a trypsin digest of ephrinA1. The mass spectra collected
were searched using Mascot Server (Matrix Science Ltd.). The
search parameters included the database SwissProt with three
missed cleavages, Mus musculus taxonomy, no variable
modifications, average mass, and a peptide tolerance of 1.2 Da.
Safety Considerations
Proper personal safety equipment was utilized when handling
solvents and solutions. The TM sprayer is designed to contain
the aerosol spray and extra precaution was considered by
placing the TM sprayer in a chemical hood for ventilation.
The TLC sprayer was used in a chemical fume hood to protect
from aerosol inhalation.
Results and Discussion
Optimization of EphrinA1 MALDI Imaging Mass
Spectrometry
Reliable detection of intact ephrinAl in heart tissue using
MALDI/TOF MS required thorough optimization of multiple
parameters. First, comparison of several MALDI matrices
DHA, CHCA, and SA revealed SA to be the optimal matrix
for detection of the intact ephrinA1 recombinant protein. Using
positive ionization linear detection, doubly charged, protonat-
ed, and dimer forms were identified in the mass spectra (Sup-
plementary Figure S1). To validate the selectivity of the stan-
dard, the sequence reported by the manufacturer was blasted
against all databases using the National Center for Biotechnol-
ogy Information (NCBI, US National Library of Medicine).
Ephrin-A1 (His tag) was found to have a 349 maximum score,
94% query coverage, and a 100% identification for ephrinA1
isoform 1 precursor [Mus musculus]. Therefore, we concluded
the analytical standard provided sufficient coverage and se-
quence overlap to accurately represent endogenous ephrinA1.
Washing has been found to significantly increase protein
detection limits by reducing the suppression of ionization nor-
mally caused by lipids and small molecules [10, 11]. We
modified previously reported methods [10, 11] to include se-
quential ethanol washes, after the tissue sections were fixed to
the ITO slides, and this significantly improved the detection of
ephrinA1. In fact, the intact protein was not detected in tissues
when the washing step was not performed (data not shown).
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For MALDI imaging, three different methods of matrix
deposition were compared: direct delivery, TLC sprayer, and
TM sprayer. The reconstructed chemical ion image for intact
ephrinA1, as well as the respective mass spectra for each
method, is shown in Figure 1. Intact protein signals were best
detected with direct delivery and utilization of the TM sprayer.
The TLC sprayer provided the lowest signal across the tissue
for ephrinA1 and was the most time-consuming during the
sample preparation process. Although ephrinA1 was detected
with all three matrix applications, the samples prepared using
the automatic TM sprayer for matrix deposition provided the
most uniform reproducible signal distributions across the tissue
(Figure 1c) attributable to the mechanism of the nozzle and the
nature of the deposition of matrix. The TM sprayer was thus
utilized to analyze cardiac tissue post-MI. We observed a
decrease in the signal for ephrinA1 in non-treated tissues.
However, due to the difficulties encountered with identification
and mass resolution, we returned to a trypsin digestion for
ephrinA1 confirmation (data not shown).
Method Validation for Imaging of Cardiac Tissue
The molecular distribution of creatine was investigated for
method validation in cardiac tissue. Creatine, which serves as
a rapid energy source in cardiac tissue via the creatine/
phospho-creatine system, is abundant in healthy cardiac tissue,
but found to be drastically reduced in infarcted ischemic tissue
[12]. The molecular ion of creatine (m/z = 132 Da) yields a
primary fragment of m/z = 90 Da. Creatine and its primary
fragment are shown in Figure 2, as detected in a section from a
healthy control (a) and post-MI heart (b). The primary fragment
of creatine presented lower signal intensity in the ischemic
region post-MI. These findings are in agreement with previous
reports correlating lower creatine levels with regions of necro-
sis, and particularly upon persisting ischemia [12]. Overall, the
data support MALDI-MSI as a valid method to image murine
cardiac tissue and elucidate molecular signatures post-MI.
EphrinA1 Expression Profile in Murine Heart
To determine ephrinA1 spatial distribution, heart sections were
subjected to trypsin digestion. A 4 h incubation provided the
highest number of identified tryptic fragments and sequence
coverage. EphrinA1-His tag standard was also spiked in
healthy control hearts prior to trypsin digestion as an analytical
control, and the observed peptides were confirmed. A repre-
sentative average mass spectrum is shown in Figure 3. Mascot
scores for ephrinA1 were 41, 25, and 25 for the standard,
spiked tissue, and tissue, respectively. The Mascot score was
low for the standard due to the nature of the analysis, the main
limiting factor being sample preparation for protein analysis in
tissue on a surface (proteins are not fully denatured and only
partially trypsinized). Taking this into consideration, the stan-
dard was treated consistently with tissue samples.
EphrinA1 sequence is listed in Figure 4a. The detected
tryptic peptides and reconstructed chemical images for selected
ephrinA1 ions detected in the control and MI hearts are shown
in Figure 4b (top and bottom, respectively). Healthy control
hearts matched with 14 out of the 25 predicted weights yielding
a 38% coverage, whereas theMI hearts only matched seven out
of the 25 masses, yielding a 34% coverage. There were five
Figure 1. Representative pictures of chemical reconstruction images for a healthy heart using three different matrix deposition
techniques: (a) direct delivery atm/z = 23783.1 (S/N 189), (b) TLC sprayer atm/z 23786.3 (S/N 10), or (c) TMsprayer atm/z = 23786.4
(S/N 97). The purple bar highlights the peak at 23.7 kDa, which represents the intact molecular ion for ephrinA1
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Figure 2. Spatial distribution of creatine (m/z = 132 Da, shown in red) in healthy control (a), and post-MI (b) murine hearts. When
creatine is subjected to MS/MS analysis, a primary fragment is observed atm/z = 90 Da, corresponding to the protonated ([M + H] +)
n-methylglycine (shown in green)
Figure 3. Mass spectra from ephrinA1 analytical standard (top panel), control tissue spiked with standard (middle panel), and
healthy control tissue (bottom panel)
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additional peptide fragments detected in the healthy tissue that
were not detected in either the standard or the MI. The reduc-
tion in the number of peptides in the MI samples is attributed to
the lower abundance of ephrinA1 post-MI, in agreement with
previous immunohistochemical and Western blot reports [1].
The experiment was repeated in n = 6 healthy control hearts
and n = 6 MI hearts. EphrinA1 matching masses presented
average protein prospector scores of 73 ± 17% and 42 ± 39%
for the healthy and MI samples, respectively. There were 25
peptides specific for ephrinA1, detected with a S/N ≥ 3, and the
frequency of detection per the sample is shown in Supplemen-
tary Figure S2.
Target Cardiac Proteins Post-MI
Further analysis was conducted in post-MI tissue comparing
proteins across specified regions. Three mass spectra were
extracted from each defined region across the injured tissue
and a Mascot search was conducted to obtain tentative protein
identification. Selected regions across the infarcted heart in-
cluded the remote (in the same plane as the injury but not
affected by the ligation), border (the intersection of injured
tissue with uninjured tissue), and injured areas shown in the
H&E stain (Figure 5a). A reconstructed chemical ion image for
m/z 617.2 shows the expression profile of ephrinA1, which was
used to define the regions for MALDI-MSI extraction
(Figure 5b). The Venn diagram in Figure 5c shows the overlap
among the number of proteins identified within the three de-
fined regions.
Supplementary Table 1 shows the top tentative protein
identifications in healthy control versus post-MI regions of
interest (remote, border, and infarct) obtained from a 4-h tryp-
sin digest. Additional protein identification was achieved by
sequence matching against Mascot, although this was not
further validated with a secondary technique. The proteins
depicted in Supplementary Table 1 warrant further investiga-
tion to elucidate the role of endogenous ephrinA1 in the car-
diomyocyte, as well as its molecular targets upon acute MI.
Specifically, pathways involved in mitochondrial energetics
and autophagic flux are of great interest to understand the
molecular mechanisms by which ephrinA1-Fc mediates pres-
ervation of myocardial tissue integrity and cardiac function
upon MI.
Using the functional annotation tool (DAVID 6.8), we
identified 18, 30, 21, and 61 clusters in the healthy remote,
border, and infarct regions, respectively (Supplementary
Table 1). As expected in healthy control hearts, the four clusters
with the highest enrichment scores (ES) were identified with
the mitochondria, nucleus, RNA processing, and the innate
immune response. In the remote region of the infarcted LV,
however, the highest ES scores were displayed by proteins
associated with altered enzymatic activity such as lyases, isom-
erases, and GTPases, indicative of increased remodeling activ-
ity [15]. Interestingly, the annotation clusters identified in the
Figure 4. EphrinA1 in heart. (a) Primary sequence of ephrinA1 with trypsin cleavage sites denoted by underlined lysine (K) or
arginine (R) amino acids. Murine sequence NCBI accession NP_034237, generated using the MS-Bridge program at http://
prospector.ucsf.edu/ allowing for one missed cleavage. (b) Expression profile of trypsinized EphrinA1 fragments: matches
between theoretical and detected fragments from a control, healthy heart (top), and after acute MI (bottom) are shown. Selected
ephrinA1 trypsin fragments that are present in a control healthy heart (m/z = 908, 1632.96, 2816.25, and 4497.11 Da) but not in the
region at risk from the infarcted heart are shown
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border region of the infarcted LV showed high ES for ribo-
somal proteins, DNA binding, and mRNA processing. These
data suggest high transcription and translational activity, which
is expected during the healing and regeneration process post-
MI (i.e., increased protein turnover) [16, 17]. The fourth anno-
tation cluster with the highest ES in the border zone was
associated with the defense response, in accordance with in-
flammation being a fundamental process during the early
stages of post-infarction myocardial remodeling [18, 19].
These are activated after ischemia and play an essential role
in several pathways to facilitate clearance of apoptotic cells and
necrotic tissue, as well as to increase metabolic activity to
compensate for the oxygen deprivation and reduced substrate
availability. Finally, annotation clusters from the infarcted LV
proteins included mitochondrial and metabolic enzymes, lipo-
proteins, phagocytic vesicles, and proteins involved in redox
processes.
Conclusions
The protocol described herein offers the ability to resolve the
anatomical distribution of endogenous myocardial ephrinA1 and
additional proteins of interest using MALDI imaging. To our
knowledge, no other technique other than immunohistochemis-
try has provided spatially resolved images of ephrinAl expres-
sion in heart tissue. MALDI-MSI provides an alternative and
significantly more powerful method that allows for customized
high-resolution images of ephrinA1. This can be achieved by an
optimal tissue sample preparation and optimization of experi-
mental and technical parameters, including tissue digestion
methods, matrix selection, matrix deposition, and spatial resolu-
tion. The optimization of this protocol would potentially aid in
the development of a new platform for the study of molecular
signatures of ischemic injury in the myocardium.
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